On the other hand, the prospective single arm AVATAR trial (also only available in abstract form) found that SBRT could delay a switch of systemic therapy (combination of a CDK 4/6 inhibitor and an aromatase inhibitor therapy) in patients with oligoprogressive luminal breast cancer [13]. This evidence concerns the gene CYP19A1 and breast carcinoma.